- Home
- LXRX vs PRTA Comparison
LXRX vs PRTA Comparison
Compare LXRX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- PRTA
- Stock Information
- Founded
- LXRX 1995
- PRTA 2012
- Country
- LXRX United States
- PRTA Ireland
- Employees
- LXRX N/A
- PRTA N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- PRTA Health Care
- Exchange
- LXRX Nasdaq
- PRTA Nasdaq
- Market Cap
- LXRX 541.5M
- PRTA 472.1M
- IPO Year
- LXRX 2000
- PRTA N/A
- Fundamental
- Price
- LXRX $1.34
- PRTA $10.54
- Analyst Decision
- LXRX Buy
- PRTA Buy
- Analyst Count
- LXRX 5
- PRTA 9
- Target Price
- LXRX $3.23
- PRTA $17.71
- AVG Volume (30 Days)
- LXRX 2.3M
- PRTA 577.8K
- Earning Date
- LXRX 11-06-2025
- PRTA 11-06-2025
- Dividend Yield
- LXRX N/A
- PRTA N/A
- EPS Growth
- LXRX N/A
- PRTA N/A
- EPS
- LXRX N/A
- PRTA N/A
- Revenue
- LXRX $70,864,000.00
- PRTA $11,786,000.00
- Revenue This Year
- LXRX $66.55
- PRTA N/A
- Revenue Next Year
- LXRX N/A
- PRTA $672.02
- P/E Ratio
- LXRX N/A
- PRTA N/A
- Revenue Growth
- LXRX 1255.21
- PRTA N/A
- 52 Week Low
- LXRX $0.28
- PRTA $4.32
- 52 Week High
- LXRX $1.66
- PRTA $17.66
- Technical
- Relative Strength Index (RSI)
- LXRX 44.82
- PRTA 54.99
- Support Level
- LXRX $1.36
- PRTA $9.75
- Resistance Level
- LXRX $1.52
- PRTA $10.90
- Average True Range (ATR)
- LXRX 0.13
- PRTA 0.60
- MACD
- LXRX -0.01
- PRTA -0.06
- Stochastic Oscillator
- LXRX 32.61
- PRTA 58.40
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.